COVID-19 revisiting inflammatory pathways of arthritis
Coronavirus disease 2019 (COVID-19) is an infectious disease, caused by severe acute respiratory syndrome coronavirus 2, which predominantly affects the lungs and, under certain circumstances, leads to an excessive or uncontrolled immune activation and cytokine…
Read More
Clinical trial disruption due to Covid-19 has begun to decline
Since early March, around 1,000 organisations supporting clinical trials as the sponsor, collaborator, or contract research organisation (CRO) have publically announced disruptions to planned and ongoing clinical trials in their press releases, Securities and Exchange…
Read More
BARDA to Fund NexoBrid Expanded Access Treatment Protocol for Thermal Burns
AMBRIDGE, Mass., May 29, 2019 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the U.S. Biomedical Advanced Research and Development…
Read More
Statement by FDA Commissioner Scott Gottlieb, M.D., Director of FDA’s Center for Drug Evaluation and Research Janet Woodcock, M.D. and Director of FDA’s Center for Biologics Evaluation and Research Peter Marks, M.D. on Expanded Access –Looking Forward
For more than 30 years, the FDA has supported patients’ access to investigational medical products for treatment, outside of participation in a clinical trial, when appropriate. The FDA remains deeply committed to this effort. Helping…
Read More
FDA Warns Against the Use of Unauthorized Devices for Diabetes Management
Today, the U.S. Food and Drug Administration is warning patients and health care professionals of risks associated with the use of unapproved or unauthorized devices for diabetes management, including continuous glucose monitoring systems, insulin pumps…
Read More
Biomarker study detects onset of Alzheimer’s up to 30 years before symptoms appear
New research from Johns Hopkins University has identified a variety of biomarkers that can be used to predict the onset of Alzheimer’s disease years before symptoms appear. The study presents nine measures, produced from several…
Read More
FDA approves first drug designed to prevent chronic migraines
The first medicine designed to prevent migraines was approved by the Food and Drug Administration on Thursday, ushering in what many experts believe will be a new era in treatment for people who suffer the…
Read More
Join Us at the 13th Clinical Trials Conference in Boston May 7th and 8th
MKR is proud to be exhibiting at 13th Clnical Trials Conference in Boston on May 7th and 8th. Details of the event can be found on their website: https://worldbigroup.com/conference/thirteenth-clinical-trials/ We encourage everyone to attend and…
Read More
Study shows drug reduces risk of relapse with neuromyelitis optica
ROCHESTER, Minn. — The drug eculizumab, a synthetic antibody that inhibits the inflammatory response, significantly reduced the risk of relapse with neuromyelitis optica spectrum disorder (NMOSD). This rare but severe autoimmune inflammatory disorder can cause…
Read More
New review identifies four hallmarks of cancer metastasis
Researchers at the University of Alabama at Birmingham and the University of Kansas Cancer Center have identified four hallmarks of cancer metastasis — when cancer has spread to different parts of the body from where…
Read More